Citigroup Inc Bio Xcel Therapeutics, Inc. Transaction History
Citigroup Inc
- $169 Billion
- Q3 2024
A detailed history of Citigroup Inc transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 3 shares of BTAI stock, worth $1. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3
Previous 55,775
99.99%
Holding current value
$1
Previous $71,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding BTAI
# of Institutions
55Shares Held
3.14MCall Options Held
22.2KPut Options Held
40.2K-
Vanguard Group Inc Valley Forge, PA1.2MShares$456,5230.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$167,4600.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$113,2560.0% of portfolio
-
Wells Fargo & Company San Francisco, CA185KShares$70,3220.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$49,3500.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $10.6M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...